BioSpace News Archive

Cogent Biosciences, Inc. reported positive initial data from the Company’s ongoing Phase 2 SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis at the 65th American Society of Hematology Annual Meeting & Exposition taking place December 9-12, 2023 in San Diego, CA.

Cipla Limited announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level.

bluebird bio, Inc. announced new and updated efficacy, safety and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel gene therapy for sickle cell disease through five years of follow-up.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed PTCL.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, announced a poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition.

Allogene Therapeutics, Inc. announced the presentation of data from a comprehensive safety review of patients treated in the Phase 1 ALPHA/ALPHA2 trials with ALLO-501/501A at the 65th Annual Meeting of the American Society of Hematology in San Diego, CA.

Blueprint Medicines Corporation announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12 in San Diego.

Bristol Myers Squibb announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent -naïve patients with lower-risk myelodysplastic syndromes who may require red blood cell transfusions.

Biomea Fusion, Inc. announced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study which will be presented in more detail at the International Conference on Advanced Technologies and Treatments of Diabetes in March 2024.

Aptose Biosciences Inc. announced that a growing body of clinical data for Aptose’s lead compound tuspetinib, demonstrates significant benefit as a single agent and in combination with venetoclax in patients with relapsed or refractory acute myeloid leukemia in the ongoing APTIVATE Phase 1/2 study.